Redeye: Enea - Next Growth Stratum
Redeye maintains its valuation and positive view of Enea, following our estimate changes yesterday. Shares still trade at a meager 13X EV/EBIT 21E. We raise our sight, beyond the Corona crisis, and expect the Stratum deal of USD 15-20m to drive solid growth from 2021.
Read more and download the research update:https://bit.ly/3d1mACc
Start following companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/about/